Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).
1 finding from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review